Boehringer Ingelheim’s third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news